Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2005 Dec;102(12):1168-74.
doi: 10.1007/s00347-005-1230-6.

[Comparison of several viral vectors for gene therapy of corneal endothelial cells]

[Article in German]
Affiliations
Comparative Study

[Comparison of several viral vectors for gene therapy of corneal endothelial cells]

[Article in German]
S C Beutelspacher et al. Ophthalmologe. 2005 Dec.

Abstract

Aim: In this paper we compare the transduction efficiency, toxicity, and safety of retroviral vectors [equine infectious anemia virus (EIAV), human immunodeficiency virus-1 (HIV-1), human foamy virus (PFV] and adenovirus (Ad) for potential use in gene therapy of corneal endothelial cells.

Method: Murine corneal endothelial cells were transduced with EIAV, HIV-1, PFV, and Ad, resulting in the overexpression of a green fluorescent protein (eGFP) transgene marker. The transduction efficiency was assessed by flow cytometry, while cytotoxicity and apoptosis rate were detected by annexin V/propidium iodide (PI) stain.

Results: Ad had the highest transduction efficiency with 99% of the cells expressing the transgene, followed by EIAV (95%), HIV-1 (75%), and PFV (43%). However, the high transduction efficiency of Ad also resulted in the highest apoptosis rate (25%) in the corneal endothelial cells. There was no detectable difference in the toxicity between PFV and HIV-1 (10%). EIAV transduction had the lowest cytotoxicity, with only 3% of the cells being annexin V/PI positive.

Conclusion: Compared to other vectors EIAV exhibited high transduction efficiency combined with low toxicity to corneal endothelial cells. Therefore, it is a powerful tool for gene therapy applications in selected corneal endothelial diseases.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Hum Gene Ther. 2000 Feb 10;11(3):439-47 - PubMed
    1. Blood. 2005 May 15;105(10):3824-32 - PubMed
    1. J Virol. 1998 Feb;72(2):1610-5 - PubMed
    1. Transplantation. 1998 Jan 15;65(1):62-7 - PubMed
    1. Graefes Arch Clin Exp Ophthalmol. 1998 Aug;236(8):602-12 - PubMed

MeSH terms

LinkOut - more resources